U.K.’s NICE Backs Esbriet, Xolair And Orencia After Getting Price Discounts

In a day of three positive recommendations helped by discounts, Bristol’s Orencia for rheumatoid arthritis, Novartis’ Xolair for Asthma and InterMune’s Esbriet for IPF finally make it onto the U.K.’s NHS payroll.